高危淋巴结阴性(N-)乳腺癌患者辅助化疗的最佳疗程:前瞻性随机多中心III期UNICANCER-PACS 05试验(UCBG-0106)的6年结果
该III期随机多中心试验纳入1515例高危淋巴结阴性早期乳腺癌患者,比较6周期与4周期FEC 100辅助化疗的疗效。中位随访6.1年,4周期较6周期无病生存(HR=1.18,95%CI 0.89-1.56,P=.24)和总生存(HR=1.39,95%CI 0.91-2.13,P=.12)风险增加均未达统计学显著。结论认为化疗疗程差异未导致结局明显不同。
要点
- 高危淋巴结阴性早期乳腺癌中,4周期与6周期FEC 100的无病生存无显著差异(HR=1.18,95%CI 0.89-1.56,P=.24)。
- 总生存同样无显著差异(HR=1.39,95%CI 0.91-2.13,P=.12)。
- 中位随访6.1年,6周期组91例(12%)事件,4周期组106例(14%)事件。
核心结论
- 在高危淋巴结阴性早期乳腺癌患者中,4周期与6周期FEC 100辅助化疗的疗程差异未导致结局明显不同,无病生存和总生存的风险增加均未达统计学显著。
研究设计与样本
- 前瞻性随机多中心III期试验,2002年至2006年纳入1515例18至65岁、淋巴结阴性高危早期乳腺癌女性,术后随机分配至6周期FEC 100(A组)或4周期FEC 100(B组)。
- 试验把握度设定为检测5年无病生存绝对差异≥6%。
主要发现
- 中位随访6.1年,A组记录91例(12%)事件,B组记录106例(14%)事件。
- 4周期对比6周期FEC 100,无病生存风险比为1.18(95%CI 0.89-1.56,P=.24),未达统计学显著。
- 总生存风险比为1.39(95%CI 0.91-2.13,P=.12),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal duration of adjuvant chemotherapy in the treatment of early-stage breast cancer remained to be investigated rigorously for the standard regimens in widespread use in North America (doxorubicin/cyclophosphamide, AC) and Europe (5-fluorouracil/epirubicin/cyclophosphamide, FEC). Whether six cycles of FEC 100 present an advantage, or not, compared with only four cycles was tested directly in a phase III prospective multicentre trial. PATIENTS AND METHODS: Between 2002 and 2006, 1515 women between 18 and 65°years of age, with node negative N(-) high-risk early-stage breast cancer, were included in the study following breast surgery and axillary lymph node dissection or procedure by sentinel node technique. Inclusion in the study required tumour size T ≥ 1 cm and at least one of the high-risk factors: T > 2 cm, negative oestrogen receptor/progesterone receptor (ER- and PR-), Scarff-Bloom-Richardson (SBR) grade II or III and age ≤ 35°years. Patients were randomly assigned to either six FEC 100 (Arm A) or four FEC 100 (Arm B). The trial was powered to detect an absolute difference ≥6% in disease-free survival (DFS) at 5°years. RESULTS: At 6.1°years median follow-up, with 91 (12%) events recorded in Arm A versus 106 (14%) in Arm B, no statistically significant risk increase was associated with four versus six FEC 100: DFS (hazard ratio (HR) = 1.18; CI 95% [0.89-1.56], P = .24) and overall survival (OS) (HR = 1.39; CI 95% [0.91-2.13], P = .12). CONCLUSION: Differences in chemotherapy duration did not induce notably different outcomes in our cohort of high-risk patients. CLINICAL TRIAL REGISTRY NUMBER: NCT00055679, Agence National de Sécurité du Médicament (ANSM) - France.
引用
- Kerbrat P, Desmoulins I, Roca L, et al. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). Eur J Cancer. 2017. PMID: 28501763. doi:10.1016/j.ejca.2017.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。